Cholesterol Efflux Self-Study Slide Library

2 AMA PRA Category 1 Credit(s)™
Launch Date:
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

No primary audience was provided.

Relevant Terms:

No primary audience was provided.

Robert S. Rosenson, MD, FACC, FAHA, FACP, FNLA

Robert S. Rosenson, MD, FACC, FAHA, FACP, FNLA
Director, Cardiometabolic Disorders
Mount Sinai Heart
Professor of Medicine
Mount Sinai School of Medicine
New York, New York

Robert S. Rosenson, MD, FACC, FAHA, FACP, is the director of cardiometabolic disorders at Mount Sinai Heart Institute and professor of medicine at Mount Sinai School of Medicine in New York City. Previously, he was the division chief of endocrinology, diabetes, and metabolism at SUNY Downstate Medical Center in Brooklyn, New York. Prior to his time in New York, Dr. Rosenson was the director of lipoprotein disorders and clinical atherosclerosis research and professor of medicine at the University of Michigan School of Medicine in Ann Arbor as well as an attending physician in the Department of Medicine of the University of Michigan Health System.
Dr. Rosenson earned his medical degree from Tulane University in New Orleans, Louisiana. He then served his residency in medicine at Brigham and Women's Hospital in Boston, Massachusetts. He later completed a fellowship in cardiology at the University of Chicago.
Dr. Rosenson has been involved in numerous grant-supported research investigations studying the effects of lipid-lowering therapy; hypoglycemic therapy; and antihypertensive agents in inflammation, thrombogenesis, and rheology. He has served as principal investigator on a number of National Institutes of Health (NIH)-funded research studies, pharmaceutical-sponsored drug trials, and multicenter studies. He has been an invited speaker at more than 150 national and international association meetings, grand rounds, and symposia. He has authored more than 600 journal articles, book chapters, abstracts, and electronic publications.
Dr. Rosenson is a diplomate of the American Board of Internal Medicine, with a subspecialty in cardiovascular disease; the National Board of Medical Examiners; and the National Lipid Association. He currently serves on a number of committees for professional societies and as a member of the Program Committee and Expert Document Committee for the American College of Cardiology. He is a fellow of the American Heart Association Council on Epidemiology and Prevention, and he is a fellow of the American Heart Association Council on Arteriosclerosis, Thrombosis, and Vascular Biology. He has been the recipient of a number of awards and honors, including the Ground-Breaking Doctors Award from Chicago magazine.

H. Bryan Brewer, Jr., MD, FNLA

H. Bryan Brewer, Jr., MD, FNLA
Director, Washington Cardiovascular Associates 
Senior Research Consultant 
Lipoprotein and Atherosclerosis Research 
MedStar Research Institute 
Washington Hospital Center 
Washington, DC

H. Bryan Brewer, Jr., MD, is director of the Washington Cardiovascular Associates and senior research consultant of lipoprotein and atherosclerosis research in the Cardiovascular Research Institute, MedStar Research Institute, Washington Hospital Center in Washington, DC. From 1976 to 2005, he held the position of chief of the Molecular Disease Branch of the National Heart, Lung, and Blood Institute (NHLBI) of the NIH in Bethesda, Maryland. 

Dr. Brewer earned his Bachelor of Science from Johns Hopkins University in Baltimore, Maryland, and his Doctorate of Medicine from Stanford University School of Medicine in Stanford, California. He completed his internship and residency training in internal medicine at Massachusetts General Hospital in Boston, Massachusetts, after which he joined the NHLBI of the NIH in Bethesda, Maryland.

Dr. Brewer's research led to the elucidation of the first published sequences for the human plasma apolipoproteins, the initial determination of the metabolism of the plasma apolipoproteins in normal and hyperlipidemic individuals, as well as the identification of multiple gene defects leading to the genetic dyslipoproteinemias. In addition, he pioneered the use of transgenic mice and rabbits as well as recombinant adenovirus vectors to identify genes that modulate lipoprotein metabolism and the development of atherosclerosis. Most recently, his research has focused on acute HDL therapy employing HDL infusions to decrease atherosclerosis in patients with acute coronary syndrome.

Dr. Brewer has been the recipient of the JD Lane Investigator Award from the Public Health Service; the Heinrich Wieland Prize from the Federal Republic of Germany; and the Public Health Service Commendation, Meritorious Service, and Distinguished Service Medals from the NIH. He has served as a member of the board of the National Cholesterol Education Program, which established treatment guidelines for patients with hyperlipidemia in the United States. He has published more than 400 original reports and 70 reviews and book chapters on the subjects of genetic dyslipoproteinemias, lipoprotein metabolism, and atherosclerosis.
1. Describe current concepts of reverse cholesterol transport (RCT) and how this process impacts total body cholesterol
2. Explain the proposed role and importance of HDL particles in mediating RCT
3. Describe the molecular mechanisms involved in cholesterol efflux from arterial macrophages
4. Discuss the role of atherosclerosis imaging for evaluating plaque composition and assisting in coronary event risk assessment.